echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shijian Biologics Trop-2 ADC declares the sixth clinical application in China

    Shijian Biologics Trop-2 ADC declares the sixth clinical application in China

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 13th, the CDE official website showed that the application for the clinical trial of the recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate of Shijian Bio/Toyo Pharmaceutical Co.


    At present, no ADC drug for this target has been approved for marketing in China.


    Kelun Botai, Duoxi Biotech, Fudan Zhangjiang, Biotech have also declared the target ADC.


    At present, there are more than 50 ADC drugs declared clinically in China, involving targets including HER2, TROP-2, CD30, c-Met, etc.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.